Canadian Customs to levy tariffs on Nycomed

Article

The Canadian Customs and Revenue Agency has decided to assess duties on Nycomed Amersham Imaging’s Omnipaque and Visipaque, according to Nycomed Amersham Canada. The move came after Mallinckrodt Medical alleged in June that Oakville, Ontario-based

The Canadian Customs and Revenue Agency has decided to assess duties on Nycomed Amersham Imaging’s Omnipaque and Visipaque, according to Nycomed Amersham Canada. The move came after Mallinckrodt Medical alleged in June that Oakville, Ontario-based Nycomed Amersham Canada was dumping its products on the Canadian market. On Nov. 15, the Canadian commissioner of customs and revenue extended the period of investigation for the charges, and on Dec. 31, made a preliminary determination that dumping had occurred. Nycomed Amersham Canada plans to contest the decision before the Canadian International Trade Tribunal, according to Jean-Pierre Huot, general manager. The tribunal will hold hearings on the case in March, Huot said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.